Sigvotatug vedotin trial failure sends Pfizer stock down nearly 3%

Traders Union
All News
Financial News
Pfizer drops 2.99% today to $23.98

Highlights

Pfizer's Phase 3 trial of sigvotatug vedotin in advanced non-small cell lung cancer failed to show a significant survival benefit, dampening near-term drug pipeline prospects.
Broader investor sentiment is pressured by CFO Dave Denton's upcoming departure and muted reaction to the company's licensing deal for SSGJ-707 outside China.
PFE trades in a sustained downtrend below major moving averages, with bearish momentum signals and a projected 2–3 day range of $23.34 to $24.27, indicating a 75% likelihood of further downside.

Pipeline setback and management exit dampen sentiment despite portfolio deal

Pfizer reported that sigvotatug vedotin, its late-stage antibody-drug conjugate for metastatic non-squamous non-small cell lung cancer, did not significantly improve overall survival in a pivotal Phase 3 trial, as reported by Finance Yahoo, Fiercebiotech, and Endpoints. This outcome reduces near-term pipeline prospects and has weighed on investor sentiment. Additional developments include the planned departure of Chief Financial Officer Dave Denton, effective August 15, 2026, for another industry, as noted by Businesswire. Pfizer also expanded its portfolio via a licensing agreement with 3SBio for SSGJ-707 rights outside China, according to Pharmexec, though price action has remained under broader selling pressure.

Oversold conditions intensify as bearish signals dominate technical landscape

Technical analysis shows PFE trading below the 20- and 50-period moving averages on the hourly chart and below the 200-period moving average on the daily chart. The Ichimoku Kijun level at $24.81 now acts as immediate resistance. Relative Strength Index (RSI) is at 19.17, confirming deep oversold conditions, while both the Stochastic RSI and Commodity Channel Index (CCI) are also in oversold territory. Selling momentum is further supported by negative signals from the Moving Average Convergence Divergence (MACD), Average Directional Index (ADX), Bull/Bear Power, and the Awesome Oscillator, all confirming downside alignment.

Downside bias prevails as narrow trading range defines near-term risk

In the next 2–3 trading days, PFE is expected to trade within a range of $23.34 to $24.27, reflecting recent volatility. The probability of an upward move is 25%, while the likelihood of continued downside is substantially higher at 75%. The baseline scenario is consolidation within this corridor; a break above $24.81 would trigger a short-term bullish move, while a decisive loss of $23.34 could accelerate declines.

Anton Kharitonov, expert at Traders Union, sees Pfizer’s technical and fundamental picture as weak following the key late-stage trial failure. Current sentiment is cautious, with persistent selling pressure dominating despite expansion efforts. Downside signals are confirmed by both technical and news-driven factors. "Base case remains range-bound action below $24.81 — until bulls reclaim this level, I expect the bias to stay negative."

Earlier, analysts noted that persistent bearish momentum leadership transitions, and strategic shifts were contributing to a cautious outlook on Pfizer shares. The latest pipeline setback and deepening oversold technical conditions further reinforce downside risk, making any sustained break above the $24.81 resistance a critical signal for sentiment reversal.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.